This Midcareer Investigator Award application seeks support to provide Dr. Freedland with protected time for patient-oriented research (POR) and to act as research mentor for junior faculty and 1 research fellow per year. Dr. Freedland's POR focuses on retrospective cohort studies with a transitioning emphasis on prospective clinical trials aimed at developing new and less toxic treatments to minimize prostate cancer treatment side effects and slow prostate cancer progression. Herein, he proposes a new trial comparing a carbohydrate-restricted diet vs. control for men with PSA recurrence after prostate cancer therapy aiming to slow the rate of PSA rise (lengthen the PSA doubling time), as an indirect measure of slowed prostate cancer growth. Secondary outcomes include weight loss and important prostate cancer biomarkers. Successful completion of this award will advance our understanding of lifestyle and other low toxicity interventions for prostate cancer as well as help educate the next generation of POR investigators.
Prostate Cancer is a major public health burden. Despite great efforts, and some progress, today, prostate cancer remains the number two cancer killer of men and a significant source of morbidity. New and less toxic treatments aimed at both minimizing treatment side-effects and slowing disease progression at sorely needed. Moreover, a new generation of investigators focused on patient-oriented research (POR) is also needed. To these ends, this Midcareer Investigator Award application seeks support to provide Dr. Freedland with protected time for POR and to act as research mentor for junior faculty and 1 research fellow per year. While Dr. Freedland's POR focus to date has been largely on retrospective cohort studies, this award coincides with a shift in his POR toward prospective clinical trials aimed at developing new and less toxic treatments to minimize prostate cancer treatment side effects and slow prostate cancer progression. Moreover, Dr. Freedland is a proven successful mentor to junior investigators in training and this award allows him to continue to spend the time necessary to mentor and help train the next generation of POR investigators.
|Howard, Lauren E; Moreira, Daniel M; De Hoedt, Amanda et al. (2017) Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int 120:E80-E86|
|Zumsteg, Zachary S; Chen, Zinan; Howard, Lauren E et al. (2017) Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate 77:1592-1600|
|Freedland, Stephen J; Vidal, Adriana C; Howard, Lauren E et al. (2017) Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer 123:4199-4206|
|Klaassen, Zachary; Howard, Lauren E; de Hoedt, Amanda et al. (2017) Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer 123:1528-1535|
|Vidal, A C; Howard, L E; Sun, S X et al. (2017) Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Prostate Cancer Prostatic Dis 20:72-78|
|Alfaqih, Mahmoud A; Nelson, Erik R; Liu, Wen et al. (2017) CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. Cancer Res 77:1662-1673|
|Allott, E H; Macias, E; Sanders, S et al. (2017) Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model. Prostate Cancer Prostatic Dis 20:165-171|
|Vidal, Adriana C; Chen, Zinan; Howard, Lauren E et al. (2017) Racial differences in prostate inflammation: results from the REDUCE study. Oncotarget 8:71393-71399|
|Allott, Emma H; Howard, Lauren E; Vidal, Adriana C et al. (2017) Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. Cancer Prev Res (Phila) 10:319-326|
|Vidal, Adriana C; Freedland, Stephen J (2017) Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping. Eur Urol 72:78-83|
Showing the most recent 10 out of 60 publications